HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Utility of bisphosphonates in treating bone metastases.

Abstract
Bone is the most common site of metastases from breast and prostate cancer, and bone destruction is characteristic of multiple myeloma. Increased osteoclast activity plays a key role in cancer-induced bone destruction. Bisphosphonates reduce osteoclastic bone resorption through various mechanisms as yet not fully elucidated. Bisphosphonates have proven to be effective in the treatment of tumor-induced hypercalcaemia. Several clinical trials indicated that these compounds can positively influence many aspects of neoplastic bone disease, however, many questions regarding their long-term efficacy and optimal therapeutic schedule await clarification from well-designed clinical trials.
AuthorsG Merlini, I Turesson
JournalMedical oncology (Northwood, London, England) (Med Oncol) Vol. 13 Issue 4 Pg. 215-21 (Dec 1996) ISSN: 1357-0560 [Print] United States
PMID9152972 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)
Chemical References
  • Antineoplastic Agents
  • Diphosphonates
Topics
  • Antineoplastic Agents (therapeutic use)
  • Bone Neoplasms (complications, drug therapy, secondary)
  • Breast Neoplasms (pathology)
  • Diphosphonates (pharmacology, therapeutic use)
  • Female
  • Humans
  • Hypercalcemia (drug therapy, etiology)
  • Male
  • Multiple Myeloma (pathology)
  • Prostatic Neoplasms (pathology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: